Valeant Pharmaceuticals Completes Acquisition of Hep-C Drug Infergen(R (Hep C Treatment)

Valeant Pharmaceuticals Completes Acquisition of Hep-C Drug Infergen(R
Genetic Engineering News - Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has completed its acquisition of the United States and Canadian rights to the hepatitis C drug Infergen(R) (interferon alfacon-1) from InterMune, Inc. (NASDAQ:ITMN) following

International Approvals: Erbitux, Peg-Intron, Rebetol
Medscape News - Dec. 27, 2005 Switzerland s regulatory authority Swissmedic has approved a new indication for cetuximab injection, allowing its use in combination with radiotherapy for the first-line treatment of locally advanced head and neck cancer. Japan's

HGS to spin off gene research
Baltimore Sun - Human Genome Sciences Inc. said yesterday that it would spin off its CoGenesys division as an independent company that will focus on the early development of the Rockville biotech's gene-based research and leave the commercialization of later-stage

What's New in Hepatitis C: Current State of the Field and Future
Medscape News - The current standard of care for the treatment of previously untreated patients with chronic hepatitis C is a combination of once-weekly injection of pegylated interferon plus daily oral ribavirin. The treatment duration is dependent on HCV genotype